title: Type 2 diabetes in children and adolescents on atypical antipsychotics.
abstract: Youth receiving treatment with antipsychotics are particularly susceptible to weight gain, type 2 diabetes (T2D), and associated metabolic disorders, which is directly associated with excess morbidity and mortality in this vulnerable population. The risk of T2D is 2- to 3-fold that of the general population, starts early in the course of treatment, and reflects the effects of weight gain in conjunction with direct effects of antipsychotics on the hypothalamus, pancreatic beta cells, and insulin-sensitive peripheral tissues. Close monitoring with early intervention through lifestyle intervention, switching away from antipsychotics with deleterious metabolic effects, and adjunctive treatment with metformin are modalities available to mitigate weight gain and improve cardiometabolic health in these patients. Despite rapidly advancing knowledge in the field, patient's access to metabolic screening and quality care remains limited. Efforts must be made to broaden reach of early cardiometabolic intervention among these patients in order to avert serious cardiovascular disease burden in the future.
authors.affiliation: Division of Nutrition, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
authors.forename: Pornpoj
authors.initials: P
authors.lastname: Pramyothin
authors.forename: Lalita
authors.initials: L
authors.lastname: Khaodhiar
mesh_terms: D000293:Adolescent; D014150:Antipsychotic Agents / Q000009:adverse effects*; D002648:Child; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D007328:Insulin / Q000378:metabolism; D008019:Life Style; D009765:Obesity / Q000139:chemically induced; D015430:Weight Gain / Q000187:drug effects
chemical_list: D014150:Antipsychotic Agents; D007328:Insulin